Tenfibgen (TBG), the carboxy-terminal fibrinogen globe domain of tenascin C, has been shown to home to tumors and to deliver anti-CK2 targeted therapies preferentially to tumor cells in xenograft models of human prostate cancer avoiding normal cells (Trembley et al. 2017). Here, TNC is linked to prostate carcinoma.